Abstract
In the modern paradigm of public health protection, much attention is paid to the health of women in peri- and postmenopause, and a personalized approach prevails. It is generally recognized that the pathogenetic therapy of menopausal disorders is hormone therapy. But the COVID-19 pandemic has made its own adjustments to the routine strategy of choosing menopausal hormone therapy (MHT). The purpose of this review was to analyze studies on the dependence of the effectiveness of MHT on clinical and genetic aspects in the context of the ongoing COVID-19 pandemic. The review highlights the main risks of MHT for thromboembolic diseases and coagulation complications characteristic of COVID-19, discusses genetic predispositions that aggravate the course of the post-COVID period, as well as the effectiveness of estrogens in protecting the vascular endothelium and increasing the number of CD4+ T cells, providing an adequate immune response when infected with SARS-CoV-2. Numerous studies show that the complications characteristic of the severe course of COVID-19 are multifactorial in nature and cannot be unambiguously explained only by genetic predisposition. However, with the development of personalized medicine, special attention should be paid to the study of genetic aspects that can equally contribute to the occurrence of menopausal disorders in healthy women and aggravate the course of the post-pregnancy period. The data presented allow us to conclude that in the context of the ongoing COVID-19 pandemic at the population level, MHT can bring significant benefits to women during menopause due to the beneficial effect of estrogens on vascular walls. Additional study of the relationship between the course of the postcovid period in MHT users and polymorphisms of candidate genes that determine the risks of thrombotic complications and metabolic consequences is required.
Publisher
Peoples' Friendship University of Russia
Reference58 articles.
1. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents
2. The NICE Guideline – Menopause: diagnosis and management
3. Peri- and postmenopause—diagnosis and interventions interdisciplinary S3 guideline of the association of the scientific medical societies in Germany (AWMF 015/062): short version
4. Khamoshina MB, Zhuravleva IS, Artemenko YS, Dmitrieva EM. Hormone-dependent diseases of the female reproductive system in the era of COVID-19: quo vadis? Obstetrics and Gynecology: news, opinions, training. 2021;9(3):35-42. https://doi.org/10.33029/23039698-2021-9-3suppI-35-42 (In Russian).
5. Ulumbekova GE, Khudova IY. Assessment of demographic, social and economic effect when taking menopausal hormone therapy. Orgzdrav: news, opinions, training. Vestnik VSHOUZ. 2020;6(4):23- 53. https://doi.org/10.24411 / 2411-8621-2020-14002 (In Russian).